Iron Chelation with Oral Deferiprone in Patients with Thalassemia
To the Editor: Olivieri et al. (Aug. 13 issue) 1 retrospectively evaluated liver-biopsy specimens from patients with thalassemia who were treated with deferiprone and concluded that progression of fibrosis in 5 of 14 patients was due to the drug. The authors minimized the potential role of known fac...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1998-12, Vol.339 (23), p.1710-1714 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1714 |
|---|---|
| container_issue | 23 |
| container_start_page | 1710 |
| container_title | The New England journal of medicine |
| container_volume | 339 |
| creator | Tricta, F Spino, M |
| description | To the Editor:
Olivieri et al. (Aug. 13 issue)
1
retrospectively evaluated liver-biopsy specimens from patients with thalassemia who were treated with deferiprone and concluded that progression of fibrosis in 5 of 14 patients was due to the drug. The authors minimized the potential role of known factors that could, on their own, explain the progression of fibrosis in the five patients and the fact that many had received inadequate chelation therapy before they started taking deferiprone. Fibrosis and even cirrhosis are prominent in patients with thalassemia, as illustrated by the fact that 3 of 18 patients had cirrhosis before treatment . . . |
| doi_str_mv | 10.1056/NEJM199812033392313 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70078790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38486172</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-58934e5de26cff7ae32245b7294138abdb315a0b84a45823da0edbd7f57bd52d3</originalsourceid><addsrcrecordid>eNqFkU1Lw0AQhhdRav34BSIED14kuruzm909llq1Uq2Heg6bZEJT8lGzCeK_dyXFg4jOZQbeZ15eZgg5Y_SaURndPM8en5gxmnEKAIYDgz0yZhIgFIJG-2RMKdehUAYOyZFzG-qLCTMiI6MjJSEak8m8bepgusbSdoWf3otuHSxbWwa3mGNbbL2MQVEHL17HunMDsVrb0jqHVWFPyEFuS4enu35MXu9mq-lDuFjez6eTRZhKoF0otQGBMkMepXmuLALnQiaKG8FA2yRLgElLEy2skJpDZilmSaZyqZJM8gyOyeXg6yO99ei6uCpcimVpa2x6FytKlVaGevDiB7hp-rb22WLOwQgd8ehfiEtjPAQDlLaNcy3m8bYtKtt-xIzGXy-If3mB3zrfWfdJhdn3zu7mXr8a9KpycY2b6k-3TwXGi3o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223948626</pqid></control><display><type>article</type><title>Iron Chelation with Oral Deferiprone in Patients with Thalassemia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Tricta, F ; Spino, M</creator><creatorcontrib>Tricta, F ; Spino, M</creatorcontrib><description>To the Editor:
Olivieri et al. (Aug. 13 issue)
1
retrospectively evaluated liver-biopsy specimens from patients with thalassemia who were treated with deferiprone and concluded that progression of fibrosis in 5 of 14 patients was due to the drug. The authors minimized the potential role of known factors that could, on their own, explain the progression of fibrosis in the five patients and the fact that many had received inadequate chelation therapy before they started taking deferiprone. Fibrosis and even cirrhosis are prominent in patients with thalassemia, as illustrated by the fact that 3 of 18 patients had cirrhosis before treatment . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199812033392313</identifier><identifier>PMID: 9867536</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>beta-Thalassemia - pathology ; Biopsy ; Humans ; Iron Chelating Agents - adverse effects ; Iron Chelating Agents - therapeutic use ; Iron Overload - drug therapy ; Iron Overload - pathology ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Pyridones - adverse effects ; Pyridones - therapeutic use</subject><ispartof>The New England journal of medicine, 1998-12, Vol.339 (23), p.1710-1714</ispartof><rights>Copyright © 1998 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts Dec 3 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-58934e5de26cff7ae32245b7294138abdb315a0b84a45823da0edbd7f57bd52d3</citedby><cites>FETCH-LOGICAL-c530t-58934e5de26cff7ae32245b7294138abdb315a0b84a45823da0edbd7f57bd52d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199812033392313$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223948626?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9867536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tricta, F</creatorcontrib><creatorcontrib>Spino, M</creatorcontrib><title>Iron Chelation with Oral Deferiprone in Patients with Thalassemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Olivieri et al. (Aug. 13 issue)
1
retrospectively evaluated liver-biopsy specimens from patients with thalassemia who were treated with deferiprone and concluded that progression of fibrosis in 5 of 14 patients was due to the drug. The authors minimized the potential role of known factors that could, on their own, explain the progression of fibrosis in the five patients and the fact that many had received inadequate chelation therapy before they started taking deferiprone. Fibrosis and even cirrhosis are prominent in patients with thalassemia, as illustrated by the fact that 3 of 18 patients had cirrhosis before treatment . . .</description><subject>beta-Thalassemia - pathology</subject><subject>Biopsy</subject><subject>Humans</subject><subject>Iron Chelating Agents - adverse effects</subject><subject>Iron Chelating Agents - therapeutic use</subject><subject>Iron Overload - drug therapy</subject><subject>Iron Overload - pathology</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Pyridones - adverse effects</subject><subject>Pyridones - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1Lw0AQhhdRav34BSIED14kuruzm909llq1Uq2Heg6bZEJT8lGzCeK_dyXFg4jOZQbeZ15eZgg5Y_SaURndPM8en5gxmnEKAIYDgz0yZhIgFIJG-2RMKdehUAYOyZFzG-qLCTMiI6MjJSEak8m8bepgusbSdoWf3otuHSxbWwa3mGNbbL2MQVEHL17HunMDsVrb0jqHVWFPyEFuS4enu35MXu9mq-lDuFjez6eTRZhKoF0otQGBMkMepXmuLALnQiaKG8FA2yRLgElLEy2skJpDZilmSaZyqZJM8gyOyeXg6yO99ei6uCpcimVpa2x6FytKlVaGevDiB7hp-rb22WLOwQgd8ehfiEtjPAQDlLaNcy3m8bYtKtt-xIzGXy-If3mB3zrfWfdJhdn3zu7mXr8a9KpycY2b6k-3TwXGi3o</recordid><startdate>19981203</startdate><enddate>19981203</enddate><creator>Tricta, F</creator><creator>Spino, M</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K0Y</scope><scope>NAPCQ</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19981203</creationdate><title>Iron Chelation with Oral Deferiprone in Patients with Thalassemia</title><author>Tricta, F ; Spino, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-58934e5de26cff7ae32245b7294138abdb315a0b84a45823da0edbd7f57bd52d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>beta-Thalassemia - pathology</topic><topic>Biopsy</topic><topic>Humans</topic><topic>Iron Chelating Agents - adverse effects</topic><topic>Iron Chelating Agents - therapeutic use</topic><topic>Iron Overload - drug therapy</topic><topic>Iron Overload - pathology</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Pyridones - adverse effects</topic><topic>Pyridones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tricta, F</creatorcontrib><creatorcontrib>Spino, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>New England Journal of Medicine</collection><collection>Nursing & Allied Health Premium</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tricta, F</au><au>Spino, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Iron Chelation with Oral Deferiprone in Patients with Thalassemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1998-12-03</date><risdate>1998</risdate><volume>339</volume><issue>23</issue><spage>1710</spage><epage>1714</epage><pages>1710-1714</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor:
Olivieri et al. (Aug. 13 issue)
1
retrospectively evaluated liver-biopsy specimens from patients with thalassemia who were treated with deferiprone and concluded that progression of fibrosis in 5 of 14 patients was due to the drug. The authors minimized the potential role of known factors that could, on their own, explain the progression of fibrosis in the five patients and the fact that many had received inadequate chelation therapy before they started taking deferiprone. Fibrosis and even cirrhosis are prominent in patients with thalassemia, as illustrated by the fact that 3 of 18 patients had cirrhosis before treatment . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>9867536</pmid><doi>10.1056/NEJM199812033392313</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1998-12, Vol.339 (23), p.1710-1714 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70078790 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | beta-Thalassemia - pathology Biopsy Humans Iron Chelating Agents - adverse effects Iron Chelating Agents - therapeutic use Iron Overload - drug therapy Iron Overload - pathology Liver Cirrhosis - etiology Liver Cirrhosis - pathology Pyridones - adverse effects Pyridones - therapeutic use |
| title | Iron Chelation with Oral Deferiprone in Patients with Thalassemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A28%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Iron%20Chelation%20with%20Oral%20Deferiprone%20in%20Patients%20with%20Thalassemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Tricta,%20F&rft.date=1998-12-03&rft.volume=339&rft.issue=23&rft.spage=1710&rft.epage=1714&rft.pages=1710-1714&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199812033392313&rft_dat=%3Cproquest_cross%3E38486172%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223948626&rft_id=info:pmid/9867536&rfr_iscdi=true |